Studies have shown that drug-resistant cancer cells, including breast, lung, and ovarian cancer and melanoma, exhibit mesenchymal-like gene expression and can be sensitized to cell death using GPX4 inhibitors; however, this phenomenon does not occur in normal cells and tumor cells that are not treated with GPX4 inhibitors [27, 28]. Here, GPX4 is linked to melanoma.